摘要
目的 :观察川芎嗪对增殖性肾炎病人血浆内皮素 (ET)和脂质过氧化物 (LPO)的影响。方法 :将 5 8例病人分为川芎嗪组 (31例 )和对照组 (2 7例 )。对照组给予泼尼松、福辛普利、双嘧达莫、环磷酰胺等治疗 ,川芎嗪组在上述治疗基础上加用川芎嗪注射液。于治疗 4wk后测定血浆内ET ,2 4h尿蛋白定量、一氧化氮 (NO)、过氧化物岐化酶 (SOD )和LPO水平变化。结果 :治疗后治疗组尿蛋白、血脂降低 ,肾功能好转 ,ET含量由 (63± 8)ng·L- 1下降为 (5 7± 8)ng·L- 1(P <0 .0 1) ;LPO含量由 (3.8± 0 .7) μmol·L- 1下降为 (1.3± 0 .8) μmol·L- 1(P<0 .0 1)。结论 :川芎嗪可通过抑制血浆ET的产生、抗脂质过氧化作用 ,对增殖性肾炎病人的肾功能有一定保护作用。
AIM: To investigate the effect of ligustrazine on the levels of endothelin (ET) and lipid peroxide (LPO) of proliferative nephritis patients. METHODS: Fifty eight patients were divided into ligustrazine group (31 patients) and control group (27 patients). Control group was given prednisone, fosinopril, dipyridamole and cyclophosphamide etc in treatment, ligustrazine group add ligastrazine base on above mentioned treatment. After 4 wk treatment, ET, 24 h urinary protein, plasma albumin (ALB), blood urea nitrogen (BUN), creatine(Cr), total cholesterol(TC), triglyceride (TG), nitrogen monxide (NO), superoxide peroxide (SOD) and LPO were measured respectively. RESULTS: With urinary protein and blood lipid decreasing and renal function improving, the concentration of ET fell from (63±8) ng·L -1 to (57±8) ng·L -1 ( P < 0.01 ) in ligustrazine group. The level of LPO decreased from (3.8±0.7) μmol·L -1 to (1.3±0.8) μmol·L -1 ( P <0.01) in ligustrazine group. CONCLUSION: This study shows that ligustrazine can protect the renal function of proliferative nephritis patients by inhibiting the production of ET and LPO.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2002年第4期239-242,共4页
Chinese Journal of New Drugs and Clinical Remedies
基金
九五科技攻关项目 ( 95 12 0 0 4 5 0 )
